Suppr超能文献

微小 RNA-105 抑制人肝癌细胞增殖并抑制 PI3K/AKT 信号通路。

MicroRNA-105 suppresses cell proliferation and inhibits PI3K/AKT signaling in human hepatocellular carcinoma.

机构信息

Department of Interventional Radiology and Vascular Anomalies, Guangzhou Women and Children's Medical Center, Guangzhou Medical University, Guangzhou, Guangdong 510623, People's Republic of China, Department of Oncology and Department of Interventional Radiology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong 510515, People's Republic of China and Department of Hepatobiliary Surgery and Department of Clinical examination, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510260, People's Republic of China.

Department of Oncology and.

出版信息

Carcinogenesis. 2014 Dec;35(12):2748-55. doi: 10.1093/carcin/bgu208. Epub 2014 Oct 3.

Abstract

A growing amount of evidence supports that microRNA (miRNA) dysregulation is involved in cancer progression by directly downregulating multiple targets. Elucidating the underlying mechanism of miRNA in carcinogenesis may improve diagnostic and therapeutic strategies for malignancy. In the current study, we found that miR-105 expression was markedly downregulated in both hepatocellular carcinoma (HCC) cell lines and clinical HCC tissues, compared with normal human hepatocyte and adjacent non-cancerous tissues, respectively. Ectopic miR-105 expression suppressed, whereas inhibiting miR-105 promoted the proliferation and tumorigenicity of HCC cells both in vitro and in vivo. Furthermore, we demonstrated that miR-105 could deactivated the phosphoinositide 3-kinase (PI3K)/AKT signaling pathway by downregulating insulin receptor substrate-1, 3-phosphoinositide-dependent protein kinase-1 and AKT1 directly, resulting in increasing cyclin-dependent kinase inhibitors 1A and 1B (p21(Cip1) and p27(Kip1)) and decreasing cyclin D1 expression in HCC. Therefore, our results suggest that miR-105 functions as a potential tumor suppressor by inhibiting the PI3K/AKT signaling pathway and might represent a potential therapeutic target for HCC patients.

摘要

越来越多的证据表明,miRNA(microRNA)失调通过直接下调多个靶标参与癌症的进展。阐明 miRNA 在致癌作用中的潜在机制可能会改善恶性肿瘤的诊断和治疗策略。在本研究中,我们发现与正常的人肝细胞和相邻的非癌组织相比,miR-105 在肝癌细胞系和临床肝癌组织中均明显下调。异位 miR-105 表达抑制,而抑制 miR-105 则在体外和体内均促进 HCC 细胞的增殖和致瘤性。此外,我们证明 miR-105 可以通过直接下调胰岛素受体底物 1、3-磷酸肌醇依赖性蛋白激酶 1 和 AKT1 来失活磷酸肌醇 3-激酶(PI3K)/AKT 信号通路,从而导致细胞周期蛋白依赖性激酶抑制剂 1A 和 1B(p21(Cip1)和 p27(Kip1)) 的表达增加和 cyclin D1 的表达减少在 HCC 中。因此,我们的结果表明,miR-105 通过抑制 PI3K/AKT 信号通路发挥潜在的肿瘤抑制作用,可能成为 HCC 患者的潜在治疗靶点。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验